In this study, we assessed the effects of peripherally administered cannabinoids in an orofacial myositis model, and the role of sex hormones in cannabinoid receptor (CBR) expression in trigeminal ganglia (TG). Peripherally administered arachidonylcyclopropylamide (ACPA), a specific CB1R agonist, significantly attenuated complete Freund's adjuvant (CFA)-induced mechanical hypersensitivity in the masseter muscle in male rats. The ACPA effect was blocked by a local administration of AM251, a specific CB1R antagonist, but not by AM630, a specific CB2R antagonist. In female rats, a 30-fold higher dose of ACPA was required to produce a moderate reduction in mechanical hypersensitivity. CFA injected in masseter muscle significantly upregulated CB1R mRNA expression in TG in male, but not in female, rats. There was a close correlation between the CB1R mRNA levels in TG and the antihyperalgesic effect of ACPA. Interleukin (IL)-1b and IL-6, which are elevated in the muscle tissue following CFA treatment, induced a significant upregulation of CB1R mRNA expression in TG from male rats. The upregulation of CB1R was prevented in TG cultures from orchidectomized male rats, which was restored by the application of testosterone. The cytokines did not alter the CB1R mRNA level in TG from intact as well as ovariectomized female rats. Neither estradiol supplement nor estrogen receptor blockade had any effects on CB1R expression. These data indicate that testosterone, but not estradiol, is required for the regulation of CB1Rs in TG under inflammatory conditions, which provide explanations for the sex differences in the antihyperalgesic effects of peripherally administered cannabinoids. Ó
Introduction
In recent years, cannabinoids have emerged as attractive alternatives or adjuncts for treatment of many types of diseases, including pain and inflammation [22] . However, psychotropic effects mediated by cannabinoid receptors (CBRs) in the central nervous system (CNS) limit the therapeutic use of cannabinoids as analgesics. Activation of peripheral CBRs, particularly CB1Rs, which are primarily expressed in primary sensory neurons, produces antinociceptive and antihyperalgesic effects in visceral, cutaneous, and muscle tissue [4,10,20,27]; and nociceptor-specific loss of CB1Rs in mice substantially reduces the analgesic effect produced by local and systemic delivery of cannabinoids [1] . These pertinent findings suggest targeting peripheral CB1R to provide effective pain relief without producing centrally mediated side effects.
It is well established that endocannabinoids produce sexually dimorphic cognitive and emotional responses [50] . Furthermore, several cannabinoids produce greater motoric effects in females [15] , and more potent analgesia in females than in males in response to noxious mechanical and heat stimuli; the effects that are mediated by centrally located CB1Rs [55, 56] . Sexually dimorphic responses in the cannabinoid system can be explained by sex differences in pharmacokinetics of cannabinoids [57] , endocannabinoid levels [9] , and CBR expression levels [11, 35] . There is no information on whether selective activation of peripheral CBRs produces sex-dependent effects, and the potential mechanisms that might lead to sex differences in the cannabinoid effects are unknown.
While factors that modulate CBR expression are not well understood, sex steroids have been implicated as potential modulators of CBR expression in the periphery. Males exhibit higher levels of CB1R mRNA than females in the rat pituitary gland, and orchidectomy in males reduces CB1R transcripts, whereas chronic exposure to estradiol in ovariectomized females decreases CB1R transcripts [18] . Similarly, CB1R density decreases in parotid glands after
